All In Biotech

Drug Trial Radar · NCT05263869

A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

An Open-label, Multi-center, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG002 in Advanced HER-2 Positive Breast Cancer Patients Previously Treated With Trastuzumab and TKIs (Magic-009)

Last checked: Nov 19, 2026Latest source record: Dec 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

99

Planned (sponsor's estimate)

Start

Mar 23, 2022

Primary completion

Dec 2022

Study completion Oct 2023

Sponsor

Lead sponsor
Shanghai Miracogen Inc.Industry
Sponsor type
Industry
First posted
Mar 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2 positive breast cancer with liver metastases.

Conditions

  • Breast Cancer With Liver Metastases

Interventions

  • MRG002Drug

    Administrated intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) by Independent Review Committee (IRC)Time frame: Baseline to study completion (up to 12 months)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fifth Medical Center of PLA General Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Sun Yat-sen Memorial Hospital

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.